Advice

in the absence of a submission from the holder of the marketing authorisation

voriconazole (Vfend) is not recommended for use within NHS Scotland.

Indication under review: Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
voriconazole (Vfend)
SMC ID:
1014/14
Indication:
Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Pharmaceutical company
Pfizer Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
10 November 2014